ClinicalTrials.gg
Status unknownNCT05669885Updated Feb 8, 2023

Hypersensitivity to Phosphodiesterase 5 Inhibition in Post-Traumatic Headache

An interventional study of Sildenafil and Placebo in Post-Traumatic Headache, sponsored by Danish Headache Center. Status unknown at 1 site in Denmark. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2023-02-08.

Sponsored by Danish Headache Center · Not applicable, Interventional, and Basic science

The sponsor has not verified this record recently (last verified Feb 2023), so the status shown — last known as Recruiting — may be out of date.
Phase
Not applicable
Study type
Interventional
Enrollment
21
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

To investigate whether sildenafil (phosphodiesterase 5 inhibitor) induces migraine-like headache in people with persistent post-traumatic headache (PTH) attributed to mild traumatic brain injury (mTBI).

02

Conditions studied

  • Post-Traumatic Headache
03

In context

Post-Traumatic Headache

194 studies on the registry are indexed under Post-Traumatic Headache; 51 are open to participants now.

This study's planned enrollment of 21 is below the median of 44 across 170 interventional studies indexed under Post-Traumatic Headache.

Browse Post-Traumatic Headache studies →

Lead sponsor

Danish Headache Center is the lead sponsor of 129 studies on the registry; 15 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 65 years of age upon entry into screening
  • History of persistent headache attributed to mild traumatic injury to the head for ≥ 12 months and in accordance with the International Classification of Headache Disorders, 3rd Edition (ICHD-3)
  • ≥ 4 monthly headache days on average across the 3 months prior to screening
  • Provision of informed consent prior to initiation of any study-specific activities/procedures

Exclusion criteria

Exclusion Criteria:

  • > 1 mild traumatic injury to the head
  • History of any primary or secondary headache disorder prior to mild traumatic injury to the head (except for infrequent episodic tension-type headache)
  • History of moderate or severe injury to the head
  • History of whiplash injury
  • History of craniotomy
  • History or evidence of any other clinically significant disorder, condition or disease (except for those outlined above) than, in the opinion of the site investigator, would pose a risk to subject safety or interfere with study evaluation, procedures or completion
  • The subject is at risk of self-harm or harm to others as evidenced by past suicidal behavior
  • Female subjects of childbearing potential with a positive pregnancy test during any study visit
  • Cardiovascular disease of any kind, including cerebrovascular diseases
  • Hypertension (systolic blood pressure of ≥150 mmHg and/or diastolic blood pressure of ≥100 mmHg) prior to the start of infusion on the experimental day
  • Hypotension (systolic blood pressure of ≤90 mmHg and/or diastolic blood pressure of ≤50 mmHg)
  • Initiation, discontinuation, or change of dosing of prophylactic medications within 2 months prior to study inclusion
  • Intake of acute medications (e.g. analgesics, triptans) within 48 hours of infusion start
  • Baseline headache intensity of >3 on an 11-point numeric rating scale (0 being no headache, 10 being the worst imaginable headache)
  • Baseline headache with migraine-like features or self-reported baseline headache that mimics the subjects' usual headache with migraine-like features
05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
21 participants (estimated)

Study arms

  • Experimental
    Sildenafil

    Oral administration of 100 mg sildenafil.

    Drug: Sildenafil

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • Study participants will be allocated to receive oral administration of 100 mg sildenafil.

  • DrugPlacebo

    Study participants will be allocated to receive oral administration of placebo.

06

What researchers measure

Primary outcomes

  1. Incidence of Migraine-Like Headache

    Difference in incidence of headache with migraine-like features (0 to 12 hours) between sildenafil and placebo.

    Time frame: 12 Hours

Secondary outcomes

  1. Headache Intensity Scores

    Difference in area under the curve (AUC) for headache intensity scores (0 to 12 hours) between sildenafil and placebo.

    Time frame: 12 Hours

07

Study locations

1 of 1 sites recruiting
  • Danish Headache Center
    Copenhagen, Denmark
    • Hakan Ashina, MD · Contact
    Recruiting
08

References and documents

Publications

  • Al-Khazali HM, Christensen RH, Melchior AG, Ashina M, Ashina H. Hypersensitivity to phosphodiesterase-5 inhibition in post-traumatic headache: Evidence of cGMP-dependent signaling. Cephalalgia. 2026 Mar;46(3):3331024261419409. doi: 10.1177/03331024261419409. Epub 2026 Mar 6. PubMed 41789856 ↗

Individual participant data

Plan to share: Undecided

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Feb 8, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05669885
Responsible party
Håkan Ashina (MD, Danish Headache Center) — Principal investigator
First posted
Jan 3, 2023
Start date
Jan 2, 2023
Primary completion
Dec 31, 2023 (estimated)
Completion
Dec 31, 2023 (estimated)
Last update
Feb 8, 2023

Study contacts

Hakan Ashina, MD
Contact
haakan.ashina@regionh.dk
+4528102495

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sildenafil

Start the discussion